Company Also Announces Completion of Enrollment in U.S. Phase II Study of Nitazoxanide in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1
TAMPA, Fla., Oct. 28 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced the presentation of studies of nitazoxanide at the upcoming 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting(R), and the 50th Anniversary Meeting of the International Association for the Study of the Liver (IASL) in San Francisco, October 31 - November 4, 2008.
-- "Evaluation of a 4 Week Lead-In Phase with Nitazoxanide (NTZ) Prior
to Peginterferon (PEGIFN) Plus NTZ for Treatment of Chronic Hepatitis C:
Final Report," J. Rossignol et al., Sunday, November 2, 4:15 PM PST
(Oral Session IASL #87), and Tuesday, November 4, 8:00 AM - 12:30 PM
PST (AASLD Presidential Poster #1848)
-- "Potential Role for Nitazoxanide in Combination with STAT-C Agents
for the Inhibition of HCV Replication Without the Development of
Resistance," Korba, et al. Sunday Nov. 2, 5:30 PM PST (Oral Session
-- "Nitazoxanide (NTZ) is an Inducer of eIF2a and PKR
phosphorylation," Elazar et al., Tuesday, November 4, 8:00 AM -
12:30 PM PST (Poster #1881)
STEALTH C-3 Fully Enrolled
In addition, Romark announced it has completed enrollment of patients into its U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C genotype 1 (STEALTH C-3). The STEALTH C-3 (Studies to Evaluate Alinia for Treatment of Hepatitis C) study began enrollment in April 2008, and 112 patients were ultimately enrolled at 13 centers in the U.S. Data from a planned interim analysis is expected in early 2009.
A Phase II randomized, double-blind, placebo-controlled clinic
|SOURCE Romark Laboratories|
Copyright©2008 PR Newswire.
All rights reserved